Mission Street, a specialist investor, developer and operator for the science and innovation sector, and BGO, a leading global real estate investment manager, have signed Orbit Discovery, a leading UK biotech company, to the duo’s purpose-built innovation district Inventa in Oxford’s West End.
Orbit Discovery, which was spun out of the University of Oxford in 2016 and provides peptide discovery services for therapeutic applications, has committed to a new lease of 8,300 sq ft and joins a growing roster of innovation companies in Oxford’s emerging central cluster for science and technology, including Nucleome Therapeutics, Xyme, and Oxford Semantic Technologies.
Colin Brown, Development Director at Mission Street, said: “We’re delighted to welcome Orbit Discovery as the latest occupier at Inventa. We have really enjoyed getting to know the team at Orbit better and we will be undertaking works in the building to provide them with exceptional space for the next period of their company growth.
“Inventa is now nearing full occupancy, housing some of Oxford’s most exciting innovation companies and establishing a thriving research and development cluster.”
Brett Rowley, VP of Finance at Orbit Discovery, said: “We spent a great deal of time testing the market in our search for our new premises, but we landed at Inventa for a variety of reasons. We were particularly drawn by the building’s central location, the unique building design and the quality of the space both in common areas and within our premises. We look forward to moving into our modern labs and office space early in the new year.”
